In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Inventor's Inventor: An Interview With Tom Fogarty

Executive Summary

For more than 40 years, Tom Fogarty has played a central role in global medical device innovation. Following a fruitful relationship with Edwards, which saw the development of the Fogarty embolectomy catheter and artficial heart valve, Fogarty went on to launch his own companies, including General Surgical, CTS, and Biopsys, to name just a few. In this interview, taken from a lecture series at Stanford University, Fogarty talks about his early days as a device innovator and how medical device innovation has changed today.
Advertisement

Related Content

The Fogarty Institute For Innovation: A Device Incubator For Difficult Times
Back Behind the Inventor's Bench: An Interview with Tom Fogarty
Back Behind the Inventor's Bench: An Interview with Tom Fogarty
More from the Device Innovators' Workbench
Obesity: Super-Sized Medical Device Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel